HbA1c Variability and Cardiovascular Events

被引：2
作者：
Mehring M. [1 ]
Donnachie E. [2 ]
Schneider A. [1 ]
机构：
[1] Institute of General Practice, University Hospital Klinikum rechts der Isar, Technische Universität München, Munich
[2] Association of Statutory Health Insurance Physicians of Bavaria-Munich, Elsenheimerstraße 39, Munich
来源：
Current Cardiovascular Risk Reports | 2016年 / 10卷 / 5期
关键词：
Cardiovascular events; HbA[!sub]1c[!/sub] variability; Health services research; Severe adverse events;
D O I：
10.1007/s12170-016-0501-x
中图分类号：
学科分类号：
摘要：
Due to its high and increasing prevalence, type 2 diabetes mellitus is becoming more and more of a global public health burden. Effective measures are required to prevent diabetes-related morbidity and the resulting premature death. The effect of long-term glycemic fluctuations in patients with diabetes mellitus, referred to as HbA1c variability, has been the subject of intensive discussion. Whereas the mean HbA1c value is already established as a risk factor for vascular complications, an accumulation of findings makes a compelling case that HbA1c variability adds further predictive value. Recent studies raise the possibility that a reduced HbA1c variability may inhibit hyperglycemia-related diseases without increasing the risk of hypoglycemia. Taken as a whole, the present evidence demonstrates a clear association between HbA1c variability and cardiovascular events in patients with type 1 and type 2 diabetes. Nevertheless, there exists to date no standardized definition or method of measuring HbA1c variability. To advance further research, it would be helpful to reach consensus on a precise definition of HbA1c variability. © 2016, Springer Science+Business Media New York.
引用
收藏
相关论文
共 33 条
  • [1] IDF diabetes atlas, (2015)
  • [2] Moss S.E., Klein R., Klein B.E., Meuer S.M., The association of glycemia and cause-specific mortality in a diabetic population, Arch Intern Med, 154, pp. 2473-2479, (1994)
  • [3] Selvin E., Marinopoulos S., Berkenblit G., Rami T., Brancati F.L., Powe N.R., Golden S.H., Meta-analysis: glycosylated hemoglobin and cardiovascular disease in diabetes mellitus, Ann Intern Med, 141, pp. 421-431, (2004)
  • [4] Gorst C., Kwok C.S., Aslam S., Buchan I., Kontopantelis E., Myint P.K., Heatlie G., Loke Y., Rutter M.K., Mamas M.A., Long-term glycemic variability and risk of adverse outcomes: a systematic review and meta-analysis, Diabetes Care, 38, pp. 2354-2369, (2015)
  • [5] Cheng D., Fei Y., Liu Y., Li J., Xue Q., Wang X., Wang N., HbA1C variability and the risk of renal status progression in diabetes mellitus: a meta-analysis, PLoS ONE, 9, (2014)
  • [6] Sugawara A., Kawai K., Motohashi S., Saito K., Kodama S., Yachi Y., Hirasawa R., Shimano H., Yamazaki K., Sone H., HbA(1c) variability and the development of microalbuminuria in type 2 diabetes: Tsukuba Kawai Diabetes Registry 2, Diabetologia, 55, pp. 2128-2131, (2012)
  • [7] Penno G., Solini A., Bonora E., Fondelli C., Orsi E., Zerbini G., Morano S., Cavalot F., Lamacchia O., Laviola L., Nicolucci A., Pugliese G., HbA1c variability as an independent correlate of nephropathy, but not retinopathy, in patients with type 2 diabetes: the Renal Insufficiency And Cardiovascular Events (RIACE) Italian multicenter study, Diabetes Care, 36, pp. 2301-2310, (2013)
  • [8] Hsu C.C., Chang H.Y., Huang M.C., Hwang S.J., Yang Y.C., Lee Y.S., Shin S.J., Tai T.Y., HbA1c variability is associated with microalbuminuria development in type 2 diabetes: a 7-year prospective cohort study, Diabetologia, 55, pp. 3163-3172, (2012)
  • [9] Luk A.O.Y., Ma R.C.W., Lau E.S.H., Yang X., Lau W.W.Y., Yu L.W.L., Chow F.C.C., Chan J.C.N., So W., Risk association of HbA1c variability with chronic kidney disease and cardiovascular disease in type 2 diabetes: prospective analysis of the Hong Kong Diabetes Registry, Diabetes Metab Res Rev, 29, pp. 384-390, (2013)
  • [10] Kilpatrick E.S., The rise and fall of HbA(1c) as a risk marker for diabetes complications, Diabetologia, 55, pp. 2089-2091, (2012)
1234